Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Receivables - Net (2020 - 2025)

Historic Receivables - Net for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $22.5 million.

  • Maravai Lifesciences Holdings' Receivables - Net fell 2171.39% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year decrease of 2171.39%. This contributed to the annual value of $38.5 million for FY2024, which is 2945.7% down from last year.
  • As of Q3 2025, Maravai Lifesciences Holdings' Receivables - Net stood at $22.5 million, which was down 2171.39% from $27.9 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Receivables - Net ranged from a high of $138.6 million in Q4 2022 and a low of $22.5 million during Q3 2025
  • Its 5-year average for Receivables - Net is $68.7 million, with a median of $54.6 million in 2023.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' Receivables - Net surged by 13033.44% in 2021 and then plummeted by 6060.93% in 2023.
  • Quarter analysis of 5 years shows Maravai Lifesciences Holdings' Receivables - Net stood at $117.5 million in 2021, then rose by 17.97% to $138.6 million in 2022, then plummeted by 60.61% to $54.6 million in 2023, then fell by 29.46% to $38.5 million in 2024, then plummeted by 41.49% to $22.5 million in 2025.
  • Its last three reported values are $22.5 million in Q3 2025, $27.9 million for Q2 2025, and $28.5 million during Q1 2025.